-DOCSTART- -X- O
Infectious -X- _ O
diseases -X- _ O
are -X- _ O
linked -X- _ O
to -X- _ O
15 -X- _ O
% -X- _ O
–20 -X- _ O
% -X- _ O
of -X- _ O
cancers -X- _ O
worldwide. -X- _ O
Among -X- _ O
them -X- _ O
, -X- _ O
Epstein–Barr -X- _ O
virus -X- _ O
( -X- _ O
EBV -X- _ O
) -X- _ O
is -X- _ O
an -X- _ O
oncogenic -X- _ O
herpesvirus -X- _ O
that -X- _ O
chronically -X- _ O
infects -X- _ O
over -X- _ O
90 -X- _ O
% -X- _ O
of -X- _ O
the -X- _ O
adult -X- _ O
population -X- _ O
, -X- _ O
with -X- _ O
over -X- _ O
200,000 -X- _ O
cases -X- _ O
of -X- _ O
cancer -X- _ O
and -X- _ O
150,000 -X- _ O
cancer-related -X- _ O
deaths -X- _ O
attributed -X- _ O
to -X- _ O
it -X- _ O
yearly. -X- _ O
Acute -X- _ O
EBV -X- _ O
infection -X- _ O
can -X- _ O
present -X- _ O
as -X- _ O
infectious -X- _ O
mononucleosis -X- _ O
, -X- _ O
and -X- _ O
lead -X- _ O
to -X- _ O
the -X- _ O
future -X- _ O
onset -X- _ O
of -X- _ O
multiple -X- _ O
cancers -X- _ O
, -X- _ O
including -X- _ O
Burkitt -X- _ O
lymphoma -X- _ O
, -X- _ O
Hodgkin -X- _ O
lymphoma -X- _ O
, -X- _ O
nasopharyngeal -X- _ O
carcinoma -X- _ O
, -X- _ O
and -X- _ O
gastric -X- _ O
carcinoma. -X- _ O
Many -X- _ O
of -X- _ O
these -X- _ O
cancers -X- _ O
express -X- _ O
latent -X- _ O
viral -X- _ O
genes -X- _ O
, -X- _ O
including -X- _ O
Epstein–Barr -X- _ O
virus -X- _ O
nuclear -X- _ O
antigen -X- _ O
1 -X- _ O
( -X- _ O
EBNA1 -X- _ O
) -X- _ O
and -X- _ O
latent -X- _ O
membrane -X- _ O
proteins -X- _ O
1 -X- _ O
and -X- _ O
2 -X- _ O
( -X- _ O
LMP1 -X- _ O
and -X- _ O
LMP2 -X- _ O
) -X- _ O
. -X- _ O
Previous -X- _ O
attempts -X- _ O
to -X- _ O
create -X- _ O
potent -X- _ O
immunogens -X- _ O
against -X- _ O
EBV -X- _ O
have -X- _ O
been -X- _ O
reported -X- _ O
but -X- _ O
generated -X- _ O
mixed -X- _ O
success. -X- _ O
We -X- _ O
designed -X- _ O
novel -X- _ B-Intervention
Synthetic -X- _ I-Intervention
Consensus -X- _ I-Intervention
( -X- _ I-Intervention
SynCon -X- _ I-Intervention
) -X- _ I-Intervention
DNA -X- _ I-Intervention
vaccines -X- _ I-Intervention
against -X- _ O
EBNA1 -X- _ B-Patient
, -X- _ I-Patient
LMP1 -X- _ I-Patient
and -X- _ I-Patient
LMP2 -X- _ I-Patient
to -X- _ O
improve -X- _ O
on -X- _ O
the -X- _ O
immune -X- _ O
potency -X- _ O
targeting -X- _ O
important -X- _ O
antigens -X- _ O
expressed -X- _ O
in -X- _ O
latently -X- _ O
infected -X- _ O
cells. -X- _ O
These -X- _ O
EBV -X- _ O
tumor -X- _ O
antigens -X- _ O
are -X- _ O
hypothesized -X- _ O
to -X- _ O
be -X- _ O
useful -X- _ O
targets -X- _ O
for -X- _ O
potential -X- _ O
immunotherapy -X- _ O
of -X- _ O
EBV-driven -X- _ O
cancers. -X- _ O
We -X- _ O
optimized -X- _ O
the -X- _ O
genetic -X- _ O
sequences -X- _ O
for -X- _ O
these -X- _ O
three -X- _ O
antigens -X- _ O
, -X- _ O
studied -X- _ O
them -X- _ O
for -X- _ O
expression -X- _ O
, -X- _ O
and -X- _ O
examined -X- _ O
their -X- _ O
immune -X- _ O
profiles -X- _ O
in -X- _ O
vivo. -X- _ O
We -X- _ O
observed -X- _ O
that -X- _ O
these -X- _ O
immunogens -X- _ O
generated -X- _ O
unique -X- _ O
profiles -X- _ O
based -X- _ O
on -X- _ O
which -X- _ O
antigen -X- _ O
was -X- _ O
delivered -X- _ O
as -X- _ O
the -X- _ O
vaccine -X- _ O
target. -X- _ O
EBNA1vax -X- _ B-Outcome
and -X- _ I-Outcome
LMP2Avax -X- _ I-Outcome
generated -X- _ I-Outcome
the -X- _ I-Outcome
most -X- _ I-Outcome
robust -X- _ I-Outcome
T -X- _ I-Outcome
cell -X- _ I-Outcome
immunity. -X- _ I-Outcome
Interestingly -X- _ I-Outcome
, -X- _ I-Outcome
LMP1vax -X- _ I-Outcome
was -X- _ I-Outcome
a -X- _ I-Outcome
very -X- _ I-Outcome
weak -X- _ I-Outcome
immunogen -X- _ I-Outcome
, -X- _ I-Outcome
generating -X- _ I-Outcome
very -X- _ I-Outcome
low -X- _ I-Outcome
levels -X- _ I-Outcome
of -X- _ I-Outcome
CD8 -X- _ I-Outcome
T -X- _ I-Outcome
cell -X- _ I-Outcome
immunity -X- _ I-Outcome
both -X- _ I-Outcome
as -X- _ I-Outcome
a -X- _ I-Outcome
standalone -X- _ I-Outcome
vaccine -X- _ I-Outcome
and -X- _ I-Outcome
as -X- _ I-Outcome
part -X- _ I-Outcome
of -X- _ I-Outcome
a -X- _ I-Outcome
trivalent -X- _ I-Outcome
vaccine -X- _ I-Outcome
cocktail. -X- _ I-Outcome
LMP2Avax -X- _ I-Outcome
was -X- _ I-Outcome
able -X- _ I-Outcome
to -X- _ I-Outcome
drive -X- _ I-Outcome
immunity -X- _ I-Outcome
that -X- _ I-Outcome
impacted -X- _ I-Outcome
EBV-antigen-positive -X- _ I-Outcome
tumor -X- _ I-Outcome
growth. -X- _ I-Outcome
These -X- _ I-Outcome
studies -X- _ I-Outcome
suggest -X- _ I-Outcome
that -X- _ I-Outcome
engineered -X- _ I-Outcome
EBV -X- _ I-Outcome
latent -X- _ I-Outcome
protein -X- _ I-Outcome
vaccines -X- _ I-Outcome
deserve -X- _ I-Outcome
additional -X- _ I-Outcome
study -X- _ I-Outcome
as -X- _ I-Outcome
potential -X- _ I-Outcome
agents -X- _ I-Outcome
for -X- _ I-Outcome
immunotherapy -X- _ I-Outcome
of -X- _ I-Outcome
EBV-driven -X- _ I-Outcome
cancers -X- _ I-Outcome
. -X- _ O

